MCID: SKN015
MIFTS: 67

Skin Carcinoma

Categories: Cancer diseases, Rare diseases, Skin diseases

Aliases & Classifications for Skin Carcinoma

MalaCards integrated aliases for Skin Carcinoma:

Name: Skin Carcinoma 12 55 15 17
Skin Cancer 12 53 55 43 3 15
Melanoma and Non-Melanoma Skin Cancer 12
Malignant Neoplasm of Skin 12
Carcinoma of Skin 12
Ca - Skin Cancer 12
Cancer of Skin 12
Skin Cancers 15
Cancer, Skin 40

Classifications:



External Ids:

Disease Ontology 12 DOID:3451 DOID:4159
MeSH 44 D012878
NCIt 50 C2920 C4914
SNOMED-CT 68 94047004
UMLS 72 C0007114 C0699893

Summaries for Skin Carcinoma

MedlinePlus : 43 Skin cancer is the most common form of cancer in the United States. The two most common types are basal cell cancer and squamous cell cancer. They usually form on the head, face, neck, hands, and arms. Another type of skin cancer, melanoma, is more dangerous but less common. Anyone can get skin cancer, but it is more common in people who Spend a lot of time in the sun or have been sunburned Have light-colored skin, hair and eyes Have a family member with skin cancer Are over age 50 You should have your doctor check any suspicious skin markings and any changes in the way your skin looks. Treatment is more likely to work well when cancer is found early. If not treated, some types of skin cancer cells can spread to other tissues and organs. Treatments include surgery, radiation therapy, chemotherapy, photodynamic therapy (PDT), and biologic therapy. PDT uses a drug and a type of laser light to kill cancer cells. Biologic therapy boosts your body's own ability to fight cancer. NIH: National Cancer Institute

MalaCards based summary : Skin Carcinoma, also known as skin cancer, is related to xeroderma pigmentosum, complementation group d and squamous cell carcinoma. An important gene associated with Skin Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Endometrial cancer and Gastric cancer. The drugs Isotretinoin and Pravastatin have been mentioned in the context of this disorder. Affiliated tissues include skin, prostate and breast, and related phenotypes are Reduced mammosphere formation and growth/size/body region

Disease Ontology : 12 An integumentary system cancer located in the skin that is the uncontrolled growth of abnormal skin cells.

CDC : 3 Skin cancer is the most common form of cancer in the United States. The two most common types of skin cancer-basal cell and squamous cell carcinomas-are highly curable, but can be disfiguring and costly to treat. Melanoma, the third most common skin cancer, is more dangerous and causes the most deaths. The majority of cases of these three types of skin cancer are caused by overexposure to ultraviolet (UV) light.

Related Diseases for Skin Carcinoma

Diseases in the Skin Carcinoma family:

Skin Carcinoma in Situ

Diseases related to Skin Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 680)
# Related Disease Score Top Affiliating Genes
1 xeroderma pigmentosum, complementation group d 32.7 XPA GSTM1 ERCC2
2 squamous cell carcinoma 32.7 TP53 PTGS2 PTCH1 IVL CTNNB1 CDH1
3 squamous cell carcinoma, head and neck 32.1 TP53 PTGS2 MYC GSTM1 CTNNB1 CDK4
4 prostate cancer 31.9 TP53 PTGS2 MYC KRT8 CTNNB1 CHGA
5 basal cell carcinoma 31.4 XPA TP53 PTCH1 MC1R KRT8 KRT20
6 merkel cell carcinoma 30.8 TP53 KRT8 KRT20 CHGA
7 melanoma, cutaneous malignant 1 30.8 TP53 MC1R CTNNB1 CDK4
8 small cell carcinoma 30.7 TP53 KRT20 CHGA
9 small cell cancer of the lung 30.6 TP53 MYC KRT20 CHGA
10 mutagen sensitivity 30.6 XPA TP53 GSTM1 ERCC2
11 lymphoepithelioma-like carcinoma 30.5 KRT8 KRT20 CDH1
12 adenoid cystic carcinoma 30.5 TP53 KRT20 CTNNB1 CDH1
13 actinic cheilitis 30.5 TP53 MSH2
14 cervical cancer 30.4 TP53 PTGS2 MYC GSTM1 CTNNB1 CDH1
15 actinic keratosis 30.4 TP53 TMC8 PTGS2 MC1R KRT20 FLG
16 suppression of tumorigenicity 12 30.4 TP53 CTNNB1 CHGA CDH1
17 xeroderma pigmentosum, variant type 30.4 XPA TP53 PTCH1 POLH ERCC2
18 keratoacanthoma 30.3 TP53 MSH2 FLG
19 adenoid squamous cell carcinoma 30.3 KRT8 KRT20 CDH1
20 lichen planus 30.3 TP53 IVL FLG
21 signet ring cell adenocarcinoma 30.3 KRT20 CHGA CDH1
22 nasopharyngeal carcinoma 30.3 TP53 MYC GSTM1 CDK4 CDH1
23 breast ductal carcinoma 30.3 TP53 KRT8 CTNNB1 CDH1
24 papilloma 30.3 TP53 KRT8 KRT20 IVL FLG
25 pharynx cancer 30.3 TP53 MYC GSTM1 CTNNB1 CDH1
26 oral cancer 30.3 TP53 PTGS2 GSTM1 CDH1
27 intrahepatic cholangiocarcinoma 30.2 TP53 KRT20 CTNNB1 CDH1
28 colon adenocarcinoma 30.2 PTGS2 KRT20 CTNNB1 CDH1
29 adenoma 30.2 TP53 PTGS2 MSH2 CTNNB1
30 sweat gland cancer 30.2 TP53 KRT8 KRT20
31 adenocarcinoma 30.1 TP53 PTGS2 MYC CTNNB1 CDK4 CDH1
32 skin benign neoplasm 30.0 XPA MSH2 KRT20
33 medulloblastoma 30.0 TP53 PTCH1 MYC CTNNB1 CDK4
34 melanoma, uveal 30.0 MC1R KRT8 CDK4
35 bowenoid papulosis 29.8 PTGS2 FLG
36 bladder cancer 29.7 TP53 MYC KRT20 GSTM1 CDK4 CDH1
37 endometrial cancer 29.7 TP53 MYC MSH2 CTNNB1 CDK4 CDH1
38 lung cancer 29.7 TP53 PTGS2 MYC KRT20 GSTM1 ERCC2
39 lung cancer susceptibility 3 29.6 TP53 PTGS2 KRT20 CTNNB1 CDK4 CDH1
40 cholangiocarcinoma 29.6 TP53 PTGS2 KRT8 KRT20 CTNNB1 CDH1
41 esophageal cancer 29.6 TP53 PTGS2 MYC GSTM1 CTNNB1 CDK4
42 brain cancer 29.6 TP53 PTCH1 MYC MSH2 GSTM1 CTNNB1
43 transitional cell carcinoma 29.5 TP53 PTGS2 MSH2 KRT8 KRT20 CDH1
44 ovarian cancer 29.4 TP53 MYC MSH2 CTNNB1 CDK4 CDH1
45 hepatocellular carcinoma 29.4 TP53 PTGS2 MYC GSTM1 CTNNB1 CDK4
46 colorectal cancer 29.3 TP53 PTGS2 MYC MSH2 KRT20 GSTM1
47 gastric cancer 29.2 TP53 PTGS2 MYC MSH2 KRT20 GSTM1
48 palmoplantar hyperkeratosis with squamous cell carcinoma of skin and 46,xx sex reversal 12.6
49 skin carcinoma in situ 12.4
50 sarcomatoid squamous cell skin carcinoma 12.2

Graphical network of the top 20 diseases related to Skin Carcinoma:



Diseases related to Skin Carcinoma

Symptoms & Phenotypes for Skin Carcinoma

GenomeRNAi Phenotypes related to Skin Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CDH1 CDK4 CHGA GSTM1 MYC POLH

MGI Mouse Phenotypes related to Skin Carcinoma:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.36 CDH1 CDK4 CHGA CTNNB1 ERCC2 KRT8
2 cellular MP:0005384 10.31 CDH1 CDK4 CTNNB1 ERCC2 MC1R MSH2
3 homeostasis/metabolism MP:0005376 10.27 CDH1 CDK4 CHGA CTNNB1 ERCC2 KRT8
4 hematopoietic system MP:0005397 10.26 CDK4 CTNNB1 ERCC2 KRT8 MC1R MSH2
5 immune system MP:0005387 10.25 CDH1 CDK4 CTNNB1 ERCC2 KRT8 MC1R
6 endocrine/exocrine gland MP:0005379 10.22 CDH1 CDK4 CHGA CTNNB1 ERCC2 MYC
7 digestive/alimentary MP:0005381 10.2 CDH1 CDK4 CTNNB1 KRT8 MSH2 MYC
8 integument MP:0010771 10.18 CDH1 CDK4 CTNNB1 ERCC2 MC1R MSH2
9 embryo MP:0005380 10.14 CDH1 CDK4 CTNNB1 KRT8 MYC PTCH1
10 craniofacial MP:0005382 10.1 CTNNB1 MC1R MYC POLH PTCH1 TP53
11 hearing/vestibular/ear MP:0005377 10.04 CTNNB1 KRT8 MC1R MYC POLH PTCH1
12 neoplasm MP:0002006 10.03 CDH1 CDK4 CTNNB1 ERCC2 MC1R MSH2
13 muscle MP:0005369 9.92 CDK4 CHGA CTNNB1 MYC PTCH1 PTGS2
14 liver/biliary system MP:0005370 9.91 CDK4 CTNNB1 KRT8 MYC PTGS2 TP53
15 no phenotypic analysis MP:0003012 9.76 CDH1 CHGA CTNNB1 MC1R MYC PTCH1
16 pigmentation MP:0001186 9.61 CDK4 CTNNB1 ERCC2 MC1R MYC POLH
17 reproductive system MP:0005389 9.36 CDH1 CDK4 CHGA CTNNB1 ERCC2 KRT8

Drugs & Therapeutics for Skin Carcinoma

Drugs for Skin Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 415)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
2
Pravastatin Approved Phase 4 81093-37-0 54687
3
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
4
Ciclopirox Approved, Investigational Phase 4 29342-05-0 2749
5
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
6
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
7
Pimecrolimus Approved, Investigational Phase 4 137071-32-0 17753757 6447131
8
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
9
Citalopram Approved Phase 4 59729-33-8 2771
10
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
11
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
12
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
13
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
14
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
15
Menthol Approved Phase 4 2216-51-5 16666
16
Tofacitinib Approved, Investigational Phase 4 477600-75-2
17
Adalimumab Approved Phase 4 331731-18-1 16219006
18
Etanercept Approved, Investigational Phase 4 185243-69-0
19
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
20
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616 46835353
21
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
22
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
23
Aminolevulinic acid Approved Phase 4 106-60-5 137
24
Vemurafenib Approved Phase 4 918504-65-1 42611257 23252090
25
Mycophenolic acid Approved Phase 4 24280-93-1 446541
26
Azathioprine Approved Phase 4 446-86-6 2265
27
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
28
Aldesleukin Approved Phase 4 85898-30-2, 110942-02-4
29
Testosterone enanthate Approved Phase 4 315-37-7 9416
30
Methyltestosterone Approved Phase 4 58-18-4 6010
31
Testosterone Approved, Experimental, Investigational Phase 4 481-30-1, 58-22-0 6013 10204
32
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
33
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
34
Epicatechin Investigational Phase 4 35323-91-2, 490-46-0 72276
35
Theobromine Investigational Phase 4 83-67-0 5429
36 Cyclooxygenase Inhibitors Phase 4
37 Anti-Inflammatory Agents Phase 4
38 Gastrointestinal Agents Phase 4
39 Cathartics Phase 4
40 Carboxymethylcellulose Sodium Phase 4
41 Laxatives Phase 4
42 Salicylates Phase 4
43 triamcinolone acetonide Phase 4
44 Triamcinolone hexacetonide Phase 4
45 Tin Fluorides Phase 4
46 Triamcinolone diacetate Phase 4
47 Vasoconstrictor Agents Phase 4
48 Antitubercular Agents Phase 4
49 insulin Phase 4
50 Insulin, Globin Zinc Phase 4

Interventional clinical trials:

(show top 50) (show all 655)
# Name Status NCT ID Phase Drugs
1 Treatment of Superficial Basal Cell Carcinoma by Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Topical Photodynamic Therapy With Methylaminolevulinate Unknown status NCT01491711 Phase 4 Methylaminolevulinate PDT in 2 sessions;Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
2 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® Unknown status NCT01553032 Phase 4 Erbitux®
3 Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
4 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Unknown status NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
5 Clinical, Laboratorial and Quality of Life Trial to Evaluate the Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea. Unknown status NCT01139749 Phase 4 oral isotretinoin;salicylic acid and ciclopirox olamine
6 The Effect on an Ionic Silver Dressing in Head and Neck Patients With Malignant Fungating Wound Unknown status NCT00813631 Phase 4
7 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4 5-fluorouracil;Placebo, vehicle control
8 Daylight Mediated Photodynamic Therapy for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL) Completed NCT02464709 Phase 4 Aminolevulinic Acid;Methyl 5-aminolevulinate
9 A Randomized, Open-Label Study to Compare the Rate of New Non-Melanoma Skin Cancer in Maintenance Renal Allograft Recipients Converted to a Sirolimus-based Regimen Versus Continuation of a Calcineurin Inhibitor-based Regimen Completed NCT00129961 Phase 4 sirolimus;cyclosporine or tacrolimus
10 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
11 Photosensitivity of the Skin Under Azathioprin in Renal Transplant Recipients Completed NCT00492895 Phase 4 Discontinuation of Azathioprin
12 A Multi-centre Double Blind Randomised Placebo-controlled Study of the Use of Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis Completed NCT01418131 Phase 4 Rectal tacrolimus;Placebo
13 Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of Actinic Keratosis on the Face in Solid Organ Transplant Recipients Completed NCT02866695 Phase 4 ingenol mebutate gel 0.015%
14 Treatment of AKs With Daylight-PDT: Comparing Two Photosensitizers (BF-200 ALA and MAL) Completed NCT01893203 Phase 4 BF-200 ALA cream;MAL cream
15 3% Dihydroxyacetone (DHA or Sunless Tanning Agent) Inhibits Vitamin D Production in the Skin in Response to Ultraviolet Light Completed NCT00818467 Phase 4
16 Phase 4 Study of Paricalcitol and Calcitriol for Reparative Management of Chronic Allograft Dysfunction and Renocardiac Syndrome in Vitamin D Insufficient Renal Transplant Recipients Completed NCT01265615 Phase 4 Paricalcitol;Calcitriol;Cholecalciferol
17 A Randomized, Double-Blinded Study of Epiceram Versus Elidel in Pediatric Subjects With Mild to Moderate Atopic Dermatitis Completed NCT00460083 Phase 4 Elidel(R) (pimecrolimus 1%)
18 A Randomized, Open-label, Assessor-blinded, Split-face Study of Imiquimod 5% Cream Applied After Cryotherapy of Actinic Keratoses Completed NCT00774787 Phase 4 imiquimod 5% cream
19 Can Vitamin D Supplementation Prevent Type 2 Diabetes by Improving Insulin Sensitivity and Secretion in Overweight Humans? Completed NCT02112721 Phase 4
20 A Randomized Open Label Study to Evaluate the Safety and Efficacy if Imiquimod 5% Cream Applied 3 Times Per Week for 8 or 12 Weeks in the Treatment of Low Risk Nodular Basal Cell Carcinoma Completed NCT00204555 Phase 4 Imiquimod
21 IL-2 Neuropsychiatric Symptoms: Mechanism and Prevention Completed NCT00352885 Phase 4 Escitalopram;Placebo;IL-2
22 Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate Completed NCT01354301 Phase 4 Thymoglobulin;Everolimus;Basiliximabe;mycophenolate sodium;Tacrolimus;Tacrolimus;Tacrolimus
23 A Prospective, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of AbobotulinumtoxinA (BTX-A) in Improving Forehead Wounds After Mohs Micrographic Surgery and Reconstruction for Skin Cancer Recruiting NCT01459666 Phase 4 Dysport (abobotulinumtoxinA);Bacteriostatic 0.9% Sodium Chloride (vehicle)
24 A Randomised Double Blind, Placebo Controlled Study of the Efficacy of Topical Menthol for Pain Relief During Topical Photodynamic Therapy Recruiting NCT02984072 Phase 4 Menthol;Aqueous Cream
25 Surgical Excision Versus Photodynamic Therapy and Topical 5-fluorouracil in Treatment of Bowen's Disease: a Multicenter Randomized Controlled Trial Recruiting NCT03909646 Phase 4 Methyl Aminolevulinate (Mal) for Topical Administration, 16.8%, 1 Gram;5Fluorouracil
26 PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS Active, not recruiting NCT02092467 Phase 4 tofacitinib;tofacitinib
27 A Phase 4 Trial Comparing the Cumulative Incidence of SCC After Treatment With Ingenol Mebutate and Imiquimod for Multiple Actinic Keratoses on Face and Scalp. A Multi-centre, Randomised, Two-arm, Open Label, Active-controlled, Parallel Group, 36-month Trial Active, not recruiting NCT01926496 Phase 4 Ingenol Mebutate Gel, 0.015%;Imiquimod Cream, 5%
28 Topical Ingenol Mebutate Versus 5% 5-fluorouracil Versus 5% Imiquimod Versus Photodynamic Therapy in Treatment of Actinic Keratosis: a Multi-centre Randomized Efficacy and Cost-effectiveness Study Active, not recruiting NCT02281682 Phase 4 Imiquimod;5-fluorouracil;Ingenol mebutate
29 COcoa Supplement and Multivitamin Outcomes Study Active, not recruiting NCT02422745 Phase 4
30 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4 Sirolimus
31 An Exploratory, Open-label Study of Sequential Field-directed Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy Terminated NCT01203878 Phase 4 Photodynamic therapy;Imiquimod
32 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4 Sirolimus;Azathioprine;Mycophenolate;Ciclosporin;Tacrolimus
33 Topical Imiquimod 5% Cream Therapy Versus Photodynamic Therapy With Methyl-aminolaevulinate 16% Cream of Actinic Keratoses in Organ Transplant Recipients Terminated NCT01538901 Phase 4 imiquimod 5% cream
34 Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4 High Dose Interleukin-2;Ipilimumab
35 A Multi-Center Study of High Dose Aldesleukin (Interleukin-2) + Vemurafenib Therapy in Patients With BRAFV600 Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4 vemurafenib + HD IL-2
36 The Effect of 90-day Oral Testosterone Therapy in Chinese Males With Type 2 Diabetes: OTEST Terminated NCT01510847 Phase 4 Andriol Testocaps
37 CERTICOEUR a Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. An Open Labelled Randomized Everolimus vs Calcineurin Inhibitors Multicenter Trial Unknown status NCT00799188 Phase 3 Everolimus
38 A Randomized Clinical Trial in the Surgical Treatment of Basal Cell Carcinoma of the Eyelid: Surgical Excision With Frozen Section vs. Permanent Section Control Unknown status NCT00663650 Phase 3
39 A RANDOMIZED, DOUBLE BLIND, MULTI-CENTER CLINICAL STUDY TO TEST THE SAFETY AND EFFICACY OF T4N5 LIPOSOME LOTION ON PATIENTS WITH XERODERMA PIGMENTOSUM IN THE PROTECTION AGAINST ACTINIC KERATOSES Unknown status NCT00002811 Phase 3 liposomal T4N5 lotion
40 Pre-emptive Cycline Treatment on Cetuximab-induced Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With an Intensified FOLFIRI. Unknown status NCT01317433 Phase 3 Doxycycline;Cetuximab
41 Continuative vs Sequential Phototherapy in Non-segmental Vitiligo Patients Unknown status NCT00525395 Phase 3
42 Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients - Multicentric Randomized, Open-label Study of Rapamycin vs Calcineurin Inhibitors Completed NCT00133887 Phase 3 rapamycin;ciclosporine;tacrolimus
43 Impact of Preoperative Acetaminophen and Carbohydrate Loading to on Pain and Functional Status in Patients Undergoing Mohs Micrographic Surgery for Non-melanoma Skin Cancers Completed NCT03131713 Phase 3 Acetaminophen
44 Chemoprevention of Skin Cancers With DFMO: A Controlled, Randomized Clinical Trial Completed NCT00005884 Phase 3 eflornithine
45 A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination With a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2*0201-Positive Patients With Previously Treated Unresectable Stage III or IV Melanoma Completed NCT00094653 Phase 3 MDX-010 (anti-CTLA4) monoclonal antibody
46 A Randomized Controlled Trial of Excisional Surgery Versus Imiquimod 5% Cream for Nodular and Superficial Basal Cell Carcinoma Completed NCT00066872 Phase 3 imiquimod
47 CSP #402 - VA Topical Tretinoin Chemoprevention Trial Completed NCT00007631 Phase 3 Tretinoin 0.1% cream or placebo
48 Open Study to Evaluate the Efficacy and Tolerance of Imiquimod 5% Cream for the Treatment of a Large and/or Multiple Superficial Basal Cell Carcinoma. Completed NCT00189280 Phase 3 Imiquimod
49 Evaluation of Pigmented Skin Lesions With MelaFind(R) System Completed NCT00434057 Phase 3
50 Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy in High-risk Cutaneous Squamous Cell Carcinoma of the Head and Neck Completed NCT00193895 Phase 3 Carboplatin

Search NIH Clinical Center for Skin Carcinoma

Genetic Tests for Skin Carcinoma

Anatomical Context for Skin Carcinoma

MalaCards organs/tissues related to Skin Carcinoma:

41
Skin, Prostate, Breast, Kidney, Lung, T Cells, Lymph Node

The Foundational Model of Anatomy Ontology organs/tissues related to Skin Carcinoma:

19
Skin

Publications for Skin Carcinoma

Articles related to Skin Carcinoma:

(show top 50) (show all 17502)
# Title Authors PMID Year
1
Auriculotemporal Nerve Involvement in Parotid Bed Malignancy. 17
30894024 2019
2
Agar pre-embedding of small skin biopsies: real-life benefits and challenges in high throughput pathology laboratories. 17
30787027 2019
3
How to Perform an Elliptical Excision of the Skin. 17
31067374 2019
4
Signaling pathways in melanosome biogenesis and pathology. 9 38
20381640 2010
5
Cyanidin suppresses ultraviolet B-induced COX-2 expression in epidermal cells by targeting MKK4, MEK1, and Raf-1. 9 38
20096264 2010
6
TGF-beta1 causes epithelial-mesenchymal transition in HaCaT derivatives, but induces expression of COX-2 and migration only in benign, not in malignant keratinocytes. 9 38
20399617 2010
7
Expression of DNA mismatch repair proteins and MSH2 polymorphisms in nonmelanoma skin cancers of organ transplant recipients. 9 38
19818066 2010
8
Melanocortin 1 receptor (MC1R), pigmentary characteristics and sun exposure: findings from a case-control study of diffuse large B-cell and follicular lymphoma. 9 38
20129839 2010
9
The neuropeptide alpha-melanocyte-stimulating hormone is critically involved in the development of cytotoxic CD8+ T cells in mice and humans. 9 38
20126537 2010
10
Predictive testing of the melanocortin 1 receptor for skin cancer and photoaging. 9 38
20066389 2010
11
MMP-10 (Stromelysin-2) and MMP-21 in human and murine squamous cell cancer. 9 38
19601983 2009
12
Aberrant trafficking of human melanocortin 1 receptor variants associated with red hair and skin cancer: Steady-state retention of mutant forms in the proximal golgi. 9 38
19452503 2009
13
The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. 9 38
19667145 2009
14
Selective inhibition of JNK with a peptide inhibitor attenuates pain hypersensitivity and tumor growth in a mouse skin cancer pain model. 9 38
19445931 2009
15
Genetic variants in pigmentation genes, pigmentary phenotypes, and risk of skin cancer in Caucasians. 9 38
19384953 2009
16
Aberrant cytokeratin expression during arsenic-induced acquired malignant phenotype in human HaCaT keratinocytes consistent with epidermal carcinogenesis. 9 38
19524636 2009
17
DNA polymerase zeta cooperates with polymerases kappa and iota in translesion DNA synthesis across pyrimidine photodimers in cells from XPV patients. 9 38
19564618 2009
18
Identification and functional analysis of novel variants of the human melanocortin 1 receptor found in melanoma patients. 9 38
19338054 2009
19
Contribution of genetic factors for melanoma susceptibility in sporadic US melanoma patients. 9 38
19320745 2009
20
p53 protein expression in skin with different levels of photoaging. 9 38
19292788 2009
21
c-Jun N-terminal kinase 1 phosphorylates Myt1 to prevent UVA-induced skin cancer. 9 38
19204086 2009
22
Vitamin D and skin cancer: a meta-analysis. 9 38
19008093 2009
23
Differential activity of UV-DDB in mouse keratinocytes and fibroblasts: impact on DNA repair and UV-induced skin cancer. 9 38
18996499 2009
24
Immunohistochemical detection of p53 protein in basal cell skin cancer after microwave-assisted antigen retrieval. 9 38
19096907 2009
25
The contribution of melanocortin 1 receptor gene polymorphisms and the agouti signalling protein gene 8818A>G polymorphism to cutaneous melanoma and basal cell carcinoma in a Polish population. 9 38
18637131 2009
26
Comparative study of nucleotide excision repair defects between XPD-mutated fibroblasts derived from trichothiodystrophy and xeroderma pigmentosum patients. 9 38
18817897 2008
27
Identification of the minimal melanocyte-specific promoter in the melanocortin receptor 1 gene. 9 38
19017395 2008
28
Persistence of repair proteins at unrepaired DNA damage distinguishes diseases with ERCC2 (XPD) mutations: cancer-prone xeroderma pigmentosum vs. non-cancer-prone trichothiodystrophy. 9 38
18470933 2008
29
Vitamin D receptor, UVR, and skin cancer: a potential protective mechanism. 9 38
18787544 2008
30
A novel AKT3 mutation in melanoma tumours and cell lines. 9 38
18813315 2008
31
Prenatal manifestation in a family affected by nevoid basal cell carcinoma syndrome. 9 38
18539553 2008
32
Overexpression of matrix metalloproteinase 1 in dermal fibroblasts from DNA repair-deficient/cancer-prone xeroderma pigmentosum group C patients. 9 38
18469853 2008
33
Polymorphisms of the VDR gene are associated with presence of solar keratoses on the skin. 9 38
18647306 2008
34
Interaction between p53 codon 72 polymorphism and melanocortin 1 receptor variants on suntan response and cutaneous melanoma risk. 9 38
18510673 2008
35
FLIP ing the coin? Death receptor-mediated signals during skin tumorigenesis. 9 38
18558995 2008
36
Degradation of HPV20E6 by p53: Delta Np63 alpha and mutant p53R248W protect the wild type p53 mediated caspase-degradation. 9 38
18412244 2008
37
p14ARF hypermethylation is common but INK4a-ARF locus or p53 mutations are rare in Merkel cell carcinoma. 9 38
18219279 2008
38
Melanocytes expressing MC1R polymorphisms associated with red hair color have altered MSH-ligand activated pigmentary responses in coculture with keratinocytes. 9 38
17960564 2008
39
Melanocortin-1 receptor signaling markedly induces the expression of the NR4A nuclear receptor subgroup in melanocytic cells. 9 38
18292087 2008
40
Nucleotide diversity and population differentiation of the melanocortin 1 receptor gene, MC1R. 9 38
18402696 2008
41
Innovative bola-surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer. 9 38
18191509 2008
42
Comparison of induced and cancer-associated mutational spectra using multivariate data analysis. 9 38
18296683 2008
43
The melanocortin 1 receptor and the UV response of human melanocytes--a shift in paradigm. 9 38
18282187 2008
44
Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). 9 38
17939062 2008
45
Melanocortin 1 receptor (MC1R) genotype influences erythemal sensitivity to psoralen-ultraviolet A photochemotherapy. 9 38
17916200 2007
46
Targeting mutant p53 shows promise for sunscreens and skin cancer. 9 38
18060027 2007
47
CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. 9 38
18060030 2007
48
p53 and the pathogenesis of skin cancer. 9 38
17270229 2007
49
Correlations between the Sonic Hedgehog pathway and basal cell carcinoma. 9 38
17988327 2007
50
Receptor function, dominant negative activity and phenotype correlations for MC1R variant alleles. 9 38
17616515 2007

Variations for Skin Carcinoma

Cosmic variations for Skin Carcinoma:

9 (show top 50) (show all 631)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6982918 YES1 skin,eye,carcinoma,squamous cell carcinoma c.851G>A p.G284E 18:743289-743289 60
2 COSM4736805 TSC1 skin,eye,carcinoma,squamous cell carcinoma c.2065C>T p.R689C 9:132903794-132903794 60
3 COSM6971614 TRAF7 skin,eye,carcinoma,squamous cell carcinoma c.349G>A p.E117K 16:2171264-2171264 60
4 COSM10660 TP53 skin,hand,carcinoma,squamous cell carcinoma c.818G>A p.R273H 17:7673802-7673802 60
5 COSM43751 TP53 skin,hand,carcinoma,squamous cell carcinoma c.673-1G>A p.? 17:7674291-7674291 60
6 COSM10705 TP53 skin,face,carcinoma,squamous cell carcinoma c.586C>T p.R196* 17:7674945-7674945 60
7 COSM44225 TP53 skin,arm,carcinoma,squamous cell carcinoma c.859G>A p.E287K 17:7673761-7673761 60
8 COSM43544 TP53 skin,face,carcinoma,squamous cell carcinoma c.260C>A p.P87Q 17:7676109-7676109 60
9 COSM10656 TP53 skin,arm,carcinoma,squamous cell carcinoma c.742C>T p.R248W 17:7674221-7674221 60
10 COSM44326 TP53 skin,face,carcinoma,squamous cell carcinoma c.706T>C p.Y236H 17:7674257-7674257 60
11 COSM44832 TP53 skin,arm,carcinoma,squamous cell carcinoma c.1096T>G p.S366A 17:7670613-7670613 60
12 COSM45830 TP53 skin,face,carcinoma,squamous cell carcinoma c.766A>C p.T256P 17:7674197-7674197 60
13 COSM45444 TP53 skin,eye,carcinoma,squamous cell carcinoma c.587G>T p.R196L 17:7674944-7674944 60
14 COSM45304 TP53 skin,face,carcinoma,squamous cell carcinoma c.375+1G>A p.? 17:7675993-7675993 60
15 COSM43588 TP53 skin,face,carcinoma,squamous cell carcinoma c.740A>C p.N247T 17:7674223-7674223 60
16 COSM10886 TP53 skin,hand,carcinoma,squamous cell carcinoma c.310C>T p.Q104* 17:7676059-7676059 60
17 COSM11081 TP53 skin,face,carcinoma,squamous cell carcinoma c.733G>T p.G245C 17:7674230-7674230 60
18 COSM10733 TP53 skin,face,carcinoma,squamous cell carcinoma c.574C>T p.Q192* 17:7674957-7674957 60
19 COSM6937552 TP53 skin,eye,carcinoma,squamous cell carcinoma c.859G>C p.E287Q 17:7673761-7673761 60
20 COSM43651 TP53 skin,face,carcinoma,squamous cell carcinoma c.763A>T p.I255F 17:7674200-7674200 60
21 COSM43753 TP53 skin,hand,carcinoma,squamous cell carcinoma c.560-1G>A p.? 17:7674972-7674972 60
22 COSM43537 TP53 skin,hand,carcinoma,squamous cell carcinoma c.565G>A p.A189T 17:7674966-7674966 60
23 COSM44923 TP53 skin,hand,carcinoma,squamous cell carcinoma c.565G>C p.A189P 17:7674966-7674966 60
24 COSM43665 TP53 skin,face,carcinoma,squamous cell carcinoma c.746G>C p.R249T 17:7674217-7674217 60
25 COSM10724 TP53 skin,eye,carcinoma,squamous cell carcinoma c.839G>C p.R280T 17:7673781-7673781 60
26 COSM46278 TP53 skin,hand,carcinoma,squamous cell carcinoma c.950A>G p.Q317R 17:7673578-7673578 60
27 COSM45145 TP53 skin,hand,carcinoma,squamous cell carcinoma c.590T>C p.V197A 17:7674941-7674941 60
28 COSM10988 TP53 skin,face,carcinoma,squamous cell carcinoma c.772G>A p.E258K 17:7674191-7674191 60
29 COSM44274 TP53 skin,hand,carcinoma,squamous cell carcinoma c.647T>A p.V216E 17:7674884-7674884 60
30 COSM45677 TP53 skin,face,carcinoma,squamous cell carcinoma c.714T>A p.C238* 17:7674249-7674249 60
31 COSM44306 TP53 skin,hand,carcinoma,squamous cell carcinoma c.845G>C p.R282P 17:7673775-7673775 60
32 COSM607136 TGFBR1 skin,neck,carcinoma,squamous cell carcinoma c.1247C>T p.S416F 9:99146601-99146601 60
33 COSM4462891 STK40 skin,eye,carcinoma,squamous cell carcinoma c.1265C>T p.S422F 1:36341798-36341798 60
34 COSM4462893 STK40 skin,eye,carcinoma,squamous cell carcinoma c.1265C>T p.S422F 1:36341798-36341798 60
35 COSM6009093 SPEN skin,eye,carcinoma,squamous cell carcinoma c.9563C>T p.P3188L 1:15935803-15935803 60
36 COSM6982915 SOX2 skin,eye,carcinoma,squamous cell carcinoma c.237G>A p.W79* 3:181712597-181712597 60
37 COSM6962965 SMO skin,neck,carcinoma,squamous cell carcinoma c.1103C>T p.P368L 7:129206332-129206332 60
38 COSM5538304 RNF43 skin,eye,carcinoma,squamous cell carcinoma c.866C>T p.S289F 17:58360235-58360235 60
39 COSM6962990 RARA skin,neck,carcinoma,squamous cell carcinoma c.1384C>T p.P462S 17:40356221-40356221 60
40 COSM5468163 RAD52 skin,eye,carcinoma,squamous cell carcinoma c.779G>A p.R260Q 12:916430-916430 60
41 COSM6962984 RAD52 skin,neck,carcinoma,squamous cell carcinoma c.439G>A p.V147M 12:927173-927173 60
42 COSM6962994 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 60
43 COSM6962992 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 60
44 COSM6962970 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1736G>A p.S579N 9:8504347-8504347 60
45 COSM456125 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.5048C>T p.S1683F 9:8341168-8341168 60
46 COSM1700914 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1261C>T p.P421S 9:8518130-8518130 60
47 COSM17489 PTCH1 skin,face,carcinoma,squamous cell carcinoma c.3724G>A p.E1242K 9:95449149-95449149 60
48 COSM221754 PPP6C skin,eye,carcinoma,squamous cell carcinoma c.790C>T p.R264C 9:125149801-125149801 60
49 COSM6962989 PLCG2 skin,neck,carcinoma,squamous cell carcinoma c.115G>T p.E39* 16:81786104-81786104 60
50 COSM6971613 PIK3R1 skin,eye,carcinoma,squamous cell carcinoma c.608A>G p.Y203C 5:68279707-68279707 60

Expression for Skin Carcinoma

Search GEO for disease gene expression data for Skin Carcinoma.

Pathways for Skin Carcinoma

Pathways related to Skin Carcinoma according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.8 TP53 MYC MSH2 CTNNB1 CDK4 CDH1
2
Show member pathways
12.67 TP53 MYC GSTM1 CTNNB1 CDK4 CDH1
3
Show member pathways
12.52 XPA TP53 POLH MYC MSH2 ERCC2
4
Show member pathways
12.41 KRT8 KRT20 IVL FLG
5 12.41 XPA TP53 POLH MSH2 ERCC2 CDK4
6 12.33 TP53 PTGS2 PTCH1 MYC MSH2 GSTM1
7 12.31 TP53 PTGS2 MYC CTNNB1 CDK4 CDH1
8 12.29 TP53 MYC CTNNB1 CDK4
9 12.29 TP53 MYC CDK4 CDH1
10 12.23 TP53 PTCH1 MYC CTNNB1
11 11.99 XPA TP53 ERCC2 CTNNB1
12 11.95 TP53 PTGS2 MYC MSH2 CTNNB1 CDH1
13 11.93 TP53 PTGS2 MYC CDK4
14 11.88 TP53 MYC CTNNB1 CDK4
15
Show member pathways
11.88 TP53 PTGS2 MYC CTNNB1 CDK4 CDH1
16 11.82 TP53 MYC MSH2 CTNNB1 CDK4 CDH1
17 11.78 TP53 PTGS2 MYC CDK4
18 11.77 TP53 MYC CDK4
19 11.73 TP53 MYC CDK4
20 11.71 MYC CTNNB1 CDH1
21 11.7 PTGS2 MYC GSTM1
22 11.66 TP53 MYC CDK4 CDH1
23 11.64 XPA TP53 ERCC2 CTNNB1
24 11.58 XPA TP53 POLH MSH2 GSTM1
25 11.5 TP53 PTGS2 MYC
26 11.42 TP53 MYC CDK4
27
Show member pathways
11.41 MYC MSH2 GSTM1
28 11.37 TP53 MYC MSH2 CDK4
29
Show member pathways
11.36 TP53 MSH2 ERCC2
30 11.29 TP53 PTGS2 KRT8
31 11.25 TP53 MYC CTNNB1
32 10.77 CTNNB1 CDH1
33 10.48 XPA POLH MSH2 GSTM1 ERCC2

GO Terms for Skin Carcinoma

Cellular components related to Skin Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.8 XPA TP53 TMC8 TMC6 PTGS2 MYC
2 flotillin complex GO:0016600 8.62 CTNNB1 CDH1

Biological processes related to Skin Carcinoma according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.93 TP53 PTCH1 MYC ERCC2 CTNNB1 CDH1
2 regulation of cell proliferation GO:0042127 9.81 PTGS2 PTCH1 CTNNB1 CDK4
3 response to toxic substance GO:0009636 9.8 XPA CDK4 CDH1
4 response to organic substance GO:0010033 9.79 PTGS2 CDK4 CDH1
5 cellular response to DNA damage stimulus GO:0006974 9.73 XPA TP53 POLH MYC MSH2 ERCC2
6 cellular response to UV GO:0034644 9.67 TP53 PTGS2 MYC
7 cornification GO:0070268 9.67 KRT8 KRT20 IVL FLG
8 determination of adult lifespan GO:0008340 9.63 TP53 MSH2
9 response to estradiol GO:0032355 9.62 PTGS2 PTCH1 MYC CTNNB1
10 postreplication repair GO:0006301 9.61 POLH MSH2
11 UV-damage excision repair GO:0070914 9.61 XPA MC1R
12 nucleotide-excision repair GO:0006289 9.61 XPA TP53 ERCC2
13 ovulation GO:0030728 9.6 PTGS2 MYC
14 response to UV-B GO:0010224 9.59 MSH2 IVL
15 negative regulation of blood vessel diameter GO:0097756 9.58 PTGS2 CHGA
16 negative regulation of cell division GO:0051782 9.58 PTCH1 MYC
17 branching involved in ureteric bud morphogenesis GO:0001658 9.58 PTCH1 MYC CTNNB1
18 entry of bacterium into host cell GO:0035635 9.57 CTNNB1 CDH1
19 hair cycle process GO:0022405 9.55 ERCC2 CTNNB1
20 in utero embryonic development GO:0001701 9.55 PTCH1 MYC MSH2 ERCC2 CTNNB1
21 hair cell differentiation GO:0035315 9.54 ERCC2 CTNNB1
22 cellular response to phorbol 13-acetate 12-myristate GO:1904628 9.52 MYC CDK4
23 cellular response to indole-3-methanol GO:0071681 9.48 CTNNB1 CDH1
24 pyrimidine dimer repair GO:0006290 9.26 POLH
25 UV protection GO:0009650 9.13 XPA MC1R ERCC2
26 response to drug GO:0042493 9.1 PTGS2 PTCH1 MYC CTNNB1 CDK4 CDH1

Molecular functions related to Skin Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 XPA TP53 TMC8 TMC6 PTGS2 PTCH1
2 enzyme binding GO:0019899 9.55 TP53 PTGS2 MSH2 GSTM1 CTNNB1
3 mechanosensitive ion channel activity GO:0008381 9.26 TMC8 TMC6
4 damaged DNA binding GO:0003684 8.92 XPA POLH MSH2 ERCC2

Sources for Skin Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....